CYP3A4 and myocardial infarction: The findings of our study demonstrated an increased risk of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.